Incyte Presents Phase 3 Results of Ruxolitinib Cream for Prurigo Nodularis at AAD 2025 Incyte (Nasdaq: INCY) today announced the results of its pivotal Phase 3 TRuE-PN clinical trial program, which includes the TRuE-PN1 and TRuE-PN2 studies. These trials evaluated…
Synseer Launches HealthBuds™ to Revolutionize Health Synseer, an innovative health and wellness company, is set to debut HealthBuds™ at the SXSW 2025 event in Austin, Texas on March 10. These next-generation earbuds are designed to do more than just provide…
Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Showing Sotyktu’s Superiority in Psoriatic Arthritis Bristol Myers Squibb (NYSE:BMY) today announced positive results from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055), which evaluated the efficacy and safety of Sotyktu (deucravacitinib)…
VTAMA® Phase 3 Data Shows Sustained Low Atopic Dermatitis Activity After Treatment-Free Interval Organon (NYSE: OGN), a global healthcare company specializing in women’s health, announced the results of a new analysis from the Phase 3 ADORING 3 open-label, long-term extension…
Nimbus Therapeutics Appoints Abbas Kazimi CEO Nimbus Therapeutics, LLC, a biotechnology company focused on designing and developing breakthrough medicines through its advanced computational drug discovery platform, has announced the appointment of Abbas Kazimi, MS, as its new Chief Executive Officer…
IMFINZI® Regimen Shows Improved Survival in Early-Stage Gastric and GEJ Cancers AstraZeneca’s innovative perioperative treatment combining IMFINZI® (durvalumab) with standard chemotherapy has shown significant improvements in survival outcomes for patients with resectable, early-stage gastric and gastroesophageal junction (GEJ) cancers. In…
Bristol Myers Squibb Gets EC Approval for Opdivo® + Yervoy® in Advanced Hepatocellular Carcinoma Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) has granted approval for the combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) as a…
Proteintech Unveils Next-Gen 3D Epitope Mapping to Boost Life Sciences Research Proteintech, a global leader in antibody and life science solutions, is proud to announce the launch of enhanced product characterization for primary antibody targets on its website (ptglab.com). The…
AAD 2025: Almirall Presents Early-Stage Pipeline and Real-World Evidence on Tirbanibulin for AK Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, showcased five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting. These presentations…
Scribe Therapeutics Presents Epigenetic X-Repressor Data at 2025 Keystone Symposium Scribe Therapeutics Inc. (Scribe), a leading genetic medicines company leveraging the power of CRISPR technology to transform human health, recently presented groundbreaking data on its Epigenetic Long-Term X-Repressor (ELXR) technology…
Auna Signs Five-Year Deal to Enhance Oncology Services in Monterrey Auna S.A. (NYSE: AUNA), a leading Latin American healthcare company with operations in Mexico, Peru, and Colombia, has announced a significant step in strengthening its oncology services in Mexico. The…
Sensorion Completes Patient Enrollment in NOTOXIS Phase 2a Trial of SENS-401 Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on developing novel therapies for hearing loss, has announced the completion of patient enrollment in its NOTOXIS Phase 2a clinical…
